FAQ: OSPRI Merger and Infectious Disease Testing Platform

What is OSPRI and how was it formed?

OSPRI is a next-generation biotechnology company formed through the merger of Community Direct DX, Scienetix, and the R&D division of Advanta Genetics, creating one of the world’s first fully vertically-integrated molecular testing platforms.

What type of testing does OSPRI specialize in?

OSPRI specializes in polymerase chain reaction (PCR)-based infectious disease detection, offering a comprehensive menu of 80+ PCR tests covering 250+ pathogens and antimicrobial resistance (AMR) genes.

What healthcare segments does OSPRI serve?

OSPRI serves women’s health, primary care, urgent care, urology, hospitals, and clinical reference laboratories, improving access to high-quality care across these key healthcare segments.

What are the key benefits of OSPRI’s technology?

OSPRI’s technology reduces overall testing costs by 20-50%, decreases testing time and workflow steps by 50-70%, increases testing capacity up to 4x, reduces lab errors through simplified workflows, and offers customized assays tailored to provider specialty and patient population.

Who is financing the merger and what is the funding amount?

The merger is financed by up to $30 million of strategic funding from Catalio Capital Management, a leading healthcare investment firm with deep expertise in diagnostics.

Who are the key leaders and scientific team members at OSPRI?

Key leaders include Steve M. Sorey (Partner), Jeremy Adamic (Partner), Dr. Rahul Sharma (Chief Science Officer), Dr. Sadia Almas (Chief Innovation Officer), and Dr. Alaina Vincent (Chief Clinical Officer).

What is OSPRI’s production capacity and growth plans?

OSPRI currently delivers over 40,000 tests per day with multilayered quality control and plans to expand its R&D team by 40% and grow commercial operations by 25% over the next 12-24 months to meet increasing demand.

Where is OSPRI headquartered and where does it operate?

OSPRI is headquartered in McKinney, Texas, and currently serves clients across 20 states and multiple clinical specialties.

What end-to-end solutions does OSPRI provide beyond assay development?

OSPRI provides manufacturing, lab buildout, revenue cycle management, and regulatory support, empowering providers to operate high-complexity labs in-house with greater speed, accuracy, and financial control.

What legacy and expertise do the founding entities bring to OSPRI?

Community Direct DX (founded 2015) has launched over 60 labs nationwide, Scienetix brings deep molecular bioengineering expertise, and Advanta R&D has led advancements in high-resolution genomics and contributed to national public health initiatives.